Total Payments
$394,009
2024 Payments
$12,824
Companies
25
Transactions
592
Medicare Patients
4,282
Medicare Billing
$4.3M
Payment Breakdown by Category
Other$304,852 (77.4%)
Travel$48,515 (12.3%)
Consulting$26,566 (6.7%)
Food & Beverage$13,106 (3.3%)
Education$970.05 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $272,788 | 140 | 69.2% |
| Travel and Lodging | $48,515 | 165 | 12.3% |
| Honoraria | $32,064 | 25 | 8.1% |
| Consulting Fee | $26,566 | 14 | 6.7% |
| Food and Beverage | $13,106 | 221 | 3.3% |
| Education | $970.05 | 27 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $191,358 | 270 | $0 (2024) |
| ABBVIE INC. | $62,014 | 82 | $0 (2024) |
| Lilly USA, LLC | $44,799 | 70 | $0 (2020) |
| GENZYME CORPORATION | $33,747 | 33 | $0 (2021) |
| Horizon Pharma plc | $22,761 | 30 | $0 (2018) |
| Horizon Therapeutics plc | $11,714 | 17 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $6,461 | 11 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $5,158 | 13 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $5,063 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $2,754 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,824 | 29 | PFIZER INC. ($6,447) |
| 2023 | $18,486 | 26 | ABBVIE INC. ($10,298) |
| 2022 | $30,082 | 43 | ABBVIE INC. ($17,794) |
| 2021 | $11,473 | 16 | PFIZER INC. ($4,555) |
| 2020 | $53,184 | 67 | PFIZER INC. ($38,175) |
| 2019 | $129,630 | 200 | PFIZER INC. ($63,574) |
| 2018 | $76,889 | 117 | PFIZER INC. ($33,425) |
| 2017 | $61,443 | 94 | PFIZER INC. ($29,541) |
All Payment Transactions
592 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $84.50 | General |
| 11/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $31.20 | General |
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Drug), RINVOQ, SKYRIZI | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $57.93 | General |
| Category: Dermatology | ||||||
| 09/17/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $645.77 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/13/2024 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/10/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $121.35 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/07/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $46.27 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/30/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,160.00 | General |
| Category: Immunology | ||||||
| 08/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.47 | General |
| 08/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $47.25 | General |
| Category: Immunology | ||||||
| 08/14/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $285.95 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/29/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/16/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $208.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/02/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $101.71 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/20/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $99.08 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/12/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $694.93 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/29/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $76.56 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.32 | General |
| Category: Dermatology | ||||||
| 05/03/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $6.61 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,179 | 90,011 | $6.4M | $1.2M |
| 2022 | 26 | 1,117 | 82,566 | $6.1M | $1.2M |
| 2021 | 28 | 1,028 | 76,041 | $5.3M | $1.1M |
| 2020 | 23 | 958 | 55,499 | $3.8M | $820,609 |
Total Patients
4,282
Total Services
304,117
Medicare Billing
$4.3M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 32 | 9,200 | $809,600 | $309,729 | 38.3% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 11 | 11,700 | $748,800 | $201,623 | 26.9% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 38 | 7,065 | $1.8M | $185,499 | 10.2% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 20 | 29,671 | $415,394 | $139,223 | 33.5% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 14 | 2,000 | $514,600 | $114,286 | 22.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 27 | 11,150 | $1.0M | $110,647 | 10.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 84 | 224 | $210,560 | $24,662 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 178 | 251 | $81,073 | $23,529 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 209 | 432 | $177,120 | $23,054 | 13.0% |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | Office | 2023 | 20 | 1,920 | $113,280 | $13,543 | 12.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 20 | 14,790 | $59,160 | $5,712 | 9.7% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 39 | 57 | $43,280 | $5,650 | 13.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 59 | 193 | $41,495 | $4,602 | 11.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 31 | $13,454 | $4,568 | 34.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 108 | 531 | $224,082 | $3,161 | 1.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $11,820 | $2,829 | 23.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 17 | 24 | $4,200 | $1,766 | 42.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 26 | $5,694 | $1,615 | 28.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $7,098 | $1,567 | 22.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 13 | $3,250 | $1,399 | 43.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 77 | $11,011 | $982.53 | 8.9% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 13 | 20 | $14,160 | $917.40 | 6.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 13 | 14 | $6,930 | $906.64 | 13.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 51 | 74 | $1,480 | $621.60 | 42.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 30 | $2,640 | $358.20 | 13.6% |
About Arthur Mandelin, MD/PHD
Arthur Mandelin, MD/PHD is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1669655569.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Arthur Mandelin, MD/PHD has received a total of $394,009 in payments from pharmaceutical and medical device companies, with $12,824 received in 2024. These payments were reported across 592 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($272,788).
As a Medicare-enrolled provider, Mandelin has provided services to 4,282 Medicare beneficiaries, totaling 304,117 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Chicago, IL
- Active Since 12/13/2007
- Last Updated 07/09/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669655569
Products in Payments
- XELJANZ (Drug) $168,971
- TALTZ (Drug) $36,943
- RINVOQ (Biological) $27,953
- KEVZARA (Drug) $26,089
- KRYSTEXXA (Drug) $22,755
- INFLECTRA (Biological) $15,583
- KRYSTEXXA (Biological) $11,731
- KEVZARA (Biological) $11,426
- Rinvoq (Biological) $9,134
- KEVZARA SARILUMAB INJECTION (Biological) $8,036
- SKYRIZI (Biological) $6,433
- OLUMIANT (Drug) $5,662
- ORENCIA (Biological) $4,748
- Humira (Biological) $2,984
- TREMFYA (Drug) $2,771
- Actemra (Biological) $2,704
- RINVOQ (Drug) $2,400
- Cimzia (Drug) $1,972
- COSENTYX (Drug) $321.94
- Durolane (Device) $149.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247